Reduced abundance of Fusobacterium signifies cardiovascular benefits of sodium glucose cotransporter 2 inhibitor in type 2 diabetes: a single arm clinical trial

Reduced abundance of Fusobacterium signifies cardiovascular benefits of sodium glucose cotransporter 2 inhibitor in type 2 diabetes: a single arm clinical trial

BackgroundThe sodium glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been demonstrated cardiovascular benefits in patients with type 2 diabetes mellitus (T2DM). However, the underlying mechanism remains poorly understood.MethodsWe conducted an 8-week, single-arm clinical trial, which en...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuhui Yang, Jiankun Deng, Xiaoxu Weng, Zhaojie Ma, Nie Lin, Yili Xiao, Rui Zuo, Yufei Hu, Canbin Zheng, Xiaoshan Zeng, Qimao Lin, Kaijian Hou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
sodium glucose cotransporter 2 inhibitor
type 2 diabetes
cardiovascular disease
gut microbiota
Fusobacterium
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1600464/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1600464/full

Similar Items